ASLAN Pharmaceuticals today announced the presentation of two posters on varlitinib at Chinese Society Of Clinical Oncology Annual Meeting
For more information, please refer to the English or Chinese press release.
Multicenter Phase 2 trial of varlitinib versus lapatinib in combination with capecit
abine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy.
JADETREE: A phase 2A, single arm, multicentre study of varlitinib plus capecitabine in Chinese patients
with advanced or metastatic biliary tract cancer (BTC).